Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to ...

Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

Eli Lilly and Co. is taking another step to bolster its genetic medicine portfolio, this time through a $2.25 billion deal ...

Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns ...

And he may be right.

Eli Lilly has more to offer than some investors realize.

Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in ...

April 28 (Reuters) - AI firm Profluent said on Tuesday it has struck a multi-program research collaboration with U.S.

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax ...

The American Hospital Association has called on federal regulators to intervene after Eli Lilly sent warning letters to 340B hospitals threatening to cut off discounted drug pricing unless they submit ...